WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq:ENCO), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, today announced the signing of a $1.7 million contract with a Japanese biotechnology company for a Phase 2 clinical trial of a new drug for Major Depressive Disorder (MDD). Encorium will provide multiple services including program consulting, project management, site management and monitoring, data management, biostatistical support, and medical writing. Revenue recognition will begin during the current third quarter and continue on a proportional performance basis over the life of the contract as services are performed.
